medigraphic.com
Instituto Nacional de Salud Pública

2022, Number 5

<< Back Next >>

salud publica mex 2022; 64 (5)

SARS-CoV-2 vaccination patterns in a private hematology and internal medicine outpatient clinic

García-Villaseñor E, Bojalil-Álvarez L, Reyes-Cisneros OA, Fernández-Gutiérrez JA, Sánchez-Bonilla D, Robles-Nasta M, Gallardo-Pérez MM, Murrieta-Álvarez I, Ruiz-Delgado GJ, Ruiz-Argüelles GJ

Language: English
References: 22
Page: 464-470
PDF size: 334.42 Kb.


ABSTRACT

Objective. Determine the proportion of vaccinated patients in a private hematology and internal medicine outpatient clinic and potential factors in adherence in at-risk patients (due to onco-hematological diseases). Materials and methods. This is a cross-sectional study of outpatients from a private clinic. We applied a non-validated instrument to all patients attending the outpatient clinic from May to October 2021. According to the primary diagnosis, we classified patients into onco-hematological and non-onco-hematological patients. Since national authorities exclusively executed and planned the rollout of vaccines, the order and eligibility defined by authorities of vaccination was considered when conducting the analysis and patients were classified according to the their corresponding group. Results. 397 participants were accrued, 269 (68%) had an onco-hematological condition. In the whole group, 73 (18.3%) had a history of infection. Vaccination history was present in 286 persons (72%); 82% had two doses. In the subset of 269 persons with an oncohematological condition, 191 (71%) were vaccinated, whereas 95 participants with non-hematological conditions (73%) had received the vaccine. Vaccination status was associated with age (OR 1.07, 95%CI: 1.03,1.10, p‹0.0001) and body mass index (OR 1.11, 95%CI: 1.04,1.17, p‹0.0001). Conclusions. According to our study, vaccination adherence at our center is significantly different from the nationwide proportion of vaccines.


REFERENCES

  1. Carvahlo T, Krammer F, Iwasaki A. The first 12 months of COVID-19:a timeline of immunological insights. Nat Rev Immunol. 2021;21:245-56.https://doi.org/10.1038/s41577-021-00522-1

  2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and riskfactors for mortality of adult inpatients with COVID-19 in Wuhan, China:a retrospective cohort study. Lancet. 2020;395(10229):1054-62. https://doi.org/10.1016/S0140-6736(20)30566-3

  3. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patientsin SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol.2020;21(3):335-7. https://doi.org/10.1016/S1470-2045(20)30096-6

  4. Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, etal. Association of clinical factors and recent anti-cancer therapy with covid-19 severity among patients with cancer: a report from the COVID-19and Cancer Consortium. Ann Oncol. 2021;32(6):787-800. https://doi.org/10.1016/j.annonc.2021.02.024

  5. Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, LeoneM, et al. Mortality in patients with cancer and coronavirus disease 2019:A systematic review and pooled analysis of 52 studies. Eur J Cancer.2020;139:43-50. https://doi.org/10.1016/j.ejca.2020.08.011

  6. Secretaría de Salud. Calendario de vacunación – Vacuna Covid. Mexico:SS, 2021 [cited 2021 Nov 23]. Available from: http://vacunacovid.gob.mx/wordpress/calendario-vacunacion/

  7. Centers for Disease Control and Prevention. Coronavirus Disease2019 (COVID-19). USA: CDC, 2021 [cited 2021 Nov 25]. Available from:https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/underlying-evidence-table.html

  8. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus pandemic (COVID-19). Our World in Data,2021 [cited 2021 Nov 23]. Available from: https://ourworldindata.org/covid-vaccinations?country=OWID_WRL

  9. Sánchez-Arenas R, Duobova SV, González-Pérez MA, Pérez-Cuevas R.Factors associated with COVID-19 preventive health behaviors amongthe general public in Mexico City and the State of Mexico. PLoS One.2021;16(7):e0254435. https://doi.org/10.1371/journal.pone.0254435

  10. Argote P, Barham E, Zukerman-Daly S, Gerez JE, Marshall J, PocasangreO. The shot, the message, and the messenger: COVID-19 vaccineacceptance in Latin America. NPJ Vaccines. 2021;6(1):118. https://doi.org/10.1038/s41541-021-00380-x

  11. Markhorst B, Zver T, Malbasic N, Dikstra R, Otto D, van der Mei R, etal. A data-driven digital application to enhance the capacity planning to theCOVID-19 vaccination process. Vaccines (Basel). 2021;9(10):1181. https://doi.org/10.3390/vaccines9101181

  12. Rahman MM, Bhattacharjee B, Farhana Z, Hamiduzzaman M, Baker-Chowdhury MA, Sorowar-Hussain M, et al. Age-related risk factors andseverity of SARS-CoV-2 infection: a systematic review and meta-analysis.J Prev Med Hyg. 2021;62(2):E329-71. https://doi.org/10.15167/2421-4248/jpmh2021.62.2.1946

  13. Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al. Clinical features andshort-term outcomes of 221 patients with COVID-19 in Wuhan, China. JClin Virol. 2020;127:104364. https://doi.org/10.1016/j.jcv.2020.104364

  14. Dessie Z, Zewotir T. Mortality-related risk factors of COVID-19: a systematicreview and meta-analysis of 42 studies and 423,117 patients. BMC InfectiousDiseases. 2021;21(1):855. https://doi.org/10.1186/s12879-021-06536-3

  15. Duobova SV, Martinez-Vega IP, Infante-Castañeda C, Aranda-Flores CE,Knaul FM, Pérez-Cuevas R. Social inequalities in supportive care needs andquality of patient-centered care of cancer patients in Mexico. Support CareCancer. 2021;29(3):1355-67. https://doi.org/10.1007/s00520-020-05615-6

  16. He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 inpersons with haematological cancers. Leukemia. 2020;34:1637-45. https://doi.org/10.1038/s41375-020-0836-7

  17. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission inpatients with cancer at a tertiary care hospital in Wuhan, China. JAMAOncol. 2020;6(7):1108-10. https://doi.org/10.1001/jamaoncol.2020.0980

  18. Chavez-McGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluationof COVID-19 mortality and adverse outcomes in US patients with orwithout cancer. JAMA Oncol. 2022;8(1):e215148. https://doi.org/10.1001/jamaoncol.2021.5148

  19. Pagano L, Salmanton-García J, Marchesi F, Lopez-García A, LamureS, Itri F, et al. COVID-19 in vaccinated adult patients with hematologicalmalignancies. Preliminary results from EPICOVIDEHA. Blood.

  20. 2022;139(10):1588-92. https://doi.org/10.1182/blood.202101412420. Chen J, Wang R, Benovich N, Wei GW. Omicron (B.1.1.529):Infectivity, vaccine breakthrough, and antibody resistance. ArXiv.2021;arXiv:2112.01318v1 [cited 2021 Nov 23]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647651/

  21. Demichelis R, Alvarado-Ibarra M, Vazques-Chávez J, Delgado-LópezN, Gómez-Cortés C, Espinosa-Bautista K, et al. Treating acute leukemiaduring the COVID-19 pandemic in an environment with limited resources:A Multicenter experience in four Latin American countries. JCOGlob Oncol. 2021;7:577-84. https://doi.org/10.1200/GO.20.00620

  22. Barbhaiya M, Levine J, Bykerk V, Mandl LA. Immunomodulatory andimmunosuppressive medication modification among patients time ofCOVID-19 vaccination. Lancet Rheumato. 2022;4(2):e85-7. https://doi.org/10.1016/S2665-9913(21)00372-6




2020     |     www.medigraphic.com